ARTICLE | Emerging Company Profile
Confluence: KINecting discovery
Confluence uses KINect to generate inhibitors of cysteine-containing kinases
November 19, 2012 8:00 AM UTC
Confluence Life Sciences Inc. is building a library of chemical probes that interact with cysteine-containing active sites of certain kinases, which could allow for quicker and more efficient discovery of inhibitors of difficult targets.
A lead molecule against MAP kinase kinase kinase 7 (MAP3K7; TAK1) is expected to begin Phase I testing in late 2014...